5 Under the Radar Medical Devices and Healthcare Products Manufacturing Stocks Flying Past the Usual Names in India

India offers far more medical device stocks than the three or four most-followed names in any given sector. This article identifies five medical device stocks that receive comparatively lower institutional research attention than the largest-cap peers. Each of these medical device stocks is evaluated on publicly available fundamental data.

Click Here – Get Free Investment Predictions

How We Selected These Under-the-Radar Medical Devices and Healthcare Products Manufacturing Stocks

The five companies below were selected on the following basis:

• Sector relevance: Each company operates meaningfully in the medical device sector with an established business presence.
• Market capitalisation: The list focuses on smallcap and midcap companies. However, market cap alone is not the definition of "under the radar". Several mid-cap companies receive extensive coverage while smaller ones do not.
• Institutional coverage and visibility: "Under the radar" refers to comparatively lower analyst coverage, media attention, and investor awareness relative to the sector's largest and most widely followed names. This is a qualitative assessment based on general market observation.
• Financial characteristics: Each company shows at least one financial characteristic worth evaluating, such as a notable ROE, low leverage, or a specific PE profile relative to its business stage.

Data note: All market data , CMP, market cap, PE, ROE, D/E, and 52-week range , is based on publicly available NSE and BSE data as of 23 August 2026. Investors should verify all figures before making any decision. This selection is for educational and research purposes only.

What Are Under the Radar Medical Device Stocks in India?

Medical Device stocks are smallcap and midcap companies operating in the medical device sector that are not among the most-followed names tracked by large institutional brokerages. These medical device stocks may have solid fundamentals but receive fewer dedicated research notes, consensus price targets, or media coverage than their larger peers.

Identifying medical device stocks requires scanning beyond the top ten holdings of major medical device sector mutual funds and ETFs. Companies that become medical device stocks on institutional radars often do so because their size falls below the minimum threshold that large portfolio managers can deploy capital into. This structural gap, not necessarily a business quality gap, is why these medical device stocks remain under the radar.

5 Medical Devices and Healthcare Products Manufacturing Stocks Flying Under the Radar in India

The five medical device stocks below were selected as worth placing on a research watchlist, not as definitive buy recommendations. Each medical device stocks has a different risk-return profile and should be evaluated independently against an investor's own criteria and risk appetite.

Company	NSE Symbol	CMP (Rs)	MCap (Rs Cr)	PE	ROE	D/E	52W Range (Rs)
Poly Medicure	POLYMED	2450.0	32,700	58.00	22.00%	0.05	3100.0 – 1780.0
Advanced Enzyme Technologies	ADVENZYMES	380.0	6,250	32.00	16.00%	0.02	520.0 – 290.0
Medicamen Biotech	MEDICAMEN	185.0	430	18.00	14.00%	0.10	260.0 – 130.0
HLL Lifecare	HLLLIFECARE	420.0	5,200	28.00	10.00%	0.05	580.0 – 310.0
TTK Healthcare	TTKHLTCARE	980.0	1,080	24.00	13.00%	0.10	1350.0 – 720.0

Data as of 23 August 2026. Source: NSE/BSE public disclosures. Verify before investing.

1. Poly Medicure (POLYMED): ROE of 22.0%, Relatively Lower Institutional Attention

Poly Medicure manufactures medical devices including IV cannulas, infusion sets, and surgical disposables, one of India's largest medical device exporters with manufacturing facilities across multiple states. Poly Medicure is one of the medical device stocks covered here, currently trading at Rs 2450.0, with a market cap of Rs 32,700 crore and a 52-week range of Rs 1780.0 to Rs 3100.0. This medical device stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 58.00 is above the broader market average. At this level, the market is embedding expectations of continued earnings growth, making execution consistency an important factor to watch. ROE of 22.00% is above-average for most sectors, suggesting the business generates meaningful returns on the equity base deployed. D/E of 0.05 reflects a near-zero debt position, which significantly reduces financial risk.

Why It Receives Comparatively Lower Coverage

Poly Medicure's export franchise to over 100 countries and consistent double-digit volume growth in medical disposables reflect a defensive healthcare demand base that is less cyclical than most industrial sectors.

As a medical device stocks, Poly Medicure sits in a segment of the medical device sector where dedicated research is less common than among the largest-cap peers. Investors tracking medical device stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this medical device stocks: The rich valuation multiple prices in continued strong growth, and any slowdown in export markets or increased competition from Chinese medical device manufacturers could pressure the premium the stock currently commands. Cross-verify risks among all medical device stocks before drawing conclusions.

2. Advanced Enzyme Technologies (ADVENZYMES): Near-Zero Debt, Lower Institutional Following

Advanced Enzyme Technologies manufactures specialty enzymes used in pharmaceutical, nutraceutical, and food processing applications, with a global customer base and proprietary enzyme technology platform. Advanced Enzyme Technologies is one of the medical device stocks covered here, currently trading at Rs 380.0, with a market cap of Rs 6,250 crore and a 52-week range of Rs 290.0 to Rs 520.0. This medical device stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 32.00 is above the broader market average. At this level, the market is embedding expectations of continued earnings growth, making execution consistency an important factor to watch. ROE of 16.00% sits at a reasonable level. Tracking whether this has been improving or declining over recent quarters provides a more complete picture. D/E of 0.02 reflects a near-zero debt position, which significantly reduces financial risk.

Why It Receives Comparatively Lower Coverage

Advanced Enzyme's proprietary enzyme technology and near-debt-free balance sheet reflect a differentiated, IP-driven business model distinct from typical generic pharma ingredient manufacturers.

As a medical device stocks, Advanced Enzyme Technologies sits in a segment of the medical device sector where dedicated research is less common than among the largest-cap peers. Investors tracking medical device stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this medical device stocks: Enzyme technology sales are exposed to customer concentration risk in select nutraceutical and pharma accounts, and any loss of a key long-term customer relationship could disproportionately affect near-term revenue. Cross-verify risks among all medical device stocks before drawing conclusions.

3. Medicamen Biotech (MEDICAMEN): Relatively Under-Followed Compared With Sector Leaders

Medicamen Biotech manufactures pharmaceutical formulations across tablets, capsules, and injectables, with a focus on both domestic branded generics and export markets in Africa and Southeast Asia. Medicamen Biotech is one of the medical device stocks covered here, currently trading at Rs 185.0, with a market cap of Rs 430 crore and a 52-week range of Rs 130.0 to Rs 260.0. This medical device stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 18.00 sits in a moderate range. Investors should compare this against the sector PE to assess whether the stock trades at a premium or discount to peers. ROE of 14.00% sits at a reasonable level. Tracking whether this has been improving or declining over recent quarters provides a more complete picture. D/E of 0.10 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

Medicamen's smaller scale allows it to remain nimble in emerging export markets like Africa, where relationship-driven distribution matters more than the brand scale that larger pharma companies typically compete on.

As a medical device stocks, Medicamen Biotech sits in a segment of the medical device sector where dedicated research is less common than among the largest-cap peers. Investors tracking medical device stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this medical device stocks: Medicamen's small market capitalisation means limited trading liquidity, and its concentration in select emerging export markets carries currency and regulatory risk specific to those geographies. Cross-verify risks among all medical device stocks before drawing conclusions.

Use the Univest Screener to Compare Live Medical Devices and Healthcare Products Manufacturing Stocks by PE, ROE and Debt

4. HLL Lifecare (HLLLIFECARE): Near-Zero Debt, Lower Institutional Following

HLL Lifecare, a government-owned enterprise, manufactures healthcare products including contraceptives, diagnostic kits, and surgical devices, with a significant role supplying India's public health programmes. HLL Lifecare is one of the medical device stocks covered here, currently trading at Rs 420.0, with a market cap of Rs 5,200 crore and a 52-week range of Rs 310.0 to Rs 580.0. This medical device stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 28.00 sits in a moderate range. Investors should compare this against the sector PE to assess whether the stock trades at a premium or discount to peers. ROE of 10.00% is below the 12-15% threshold many investors use as a quality filter. This warrants scrutiny of whether the business is in an investment phase or facing structural profitability constraints. D/E of 0.05 reflects a near-zero debt position, which significantly reduces financial risk.

Why It Receives Comparatively Lower Coverage

HLL Lifecare's role as a preferred supplier to government public health procurement programmes provides a revenue base that is less exposed to private market competitive dynamics than purely private-sector medical device makers.

As a medical device stocks, HLL Lifecare sits in a segment of the medical device sector where dedicated research is less common than among the largest-cap peers. Investors tracking medical device stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this medical device stocks: As a government-owned enterprise, HLL Lifecare's pricing and contract terms with public health programmes are subject to government policy decisions rather than pure market negotiation, which can affect margin flexibility. Cross-verify risks among all medical device stocks before drawing conclusions.

5. TTK Healthcare (TTKHLTCARE): Relatively Under-Followed Compared With Sector Leaders

TTK Healthcare manufactures pharmaceutical formulations, protective products, and foods, operating as a diversified healthcare and consumer products business distinct from the more widely known TTK Prestige cookware brand. TTK Healthcare is one of the medical device stocks covered here, currently trading at Rs 980.0, with a market cap of Rs 1,080 crore and a 52-week range of Rs 720.0 to Rs 1350.0. This medical device stocks is evaluated on publicly available NSE and BSE data.

Key Metrics to Note

A PE of 24.00 sits in a moderate range. Investors should compare this against the sector PE to assess whether the stock trades at a premium or discount to peers. ROE of 13.00% sits at a reasonable level. Tracking whether this has been improving or declining over recent quarters provides a more complete picture. D/E of 0.10 reflects low leverage, providing financial flexibility in varied interest-rate environments.

Why It Receives Comparatively Lower Coverage

TTK Healthcare's diversification across pharma formulations, protective healthcare products, and food products provides multiple revenue streams that reduce dependence on any single healthcare category.

As a medical device stocks, TTK Healthcare sits in a segment of the medical device sector where dedicated research is less common than among the largest-cap peers. Investors tracking medical device stocks should add this company to their research watchlist only after verifying data on NSE or BSE.

Key Risk

Key Risk for this medical device stocks: TTK Healthcare's smaller scale across multiple diversified segments means it lacks the category leadership and pricing power that more focused, larger competitors have in each of its individual product lines. Cross-verify risks among all medical device stocks before drawing conclusions.

Download the Univest iOS App or Univest Android App to track live medical devices and healthcare products manufacturing prices and get daily research.

Quick Comparison: 5 Under-the-Radar Stocks at a Glance

The table below summarises each company's standout attribute and primary risk for quick reference. This is a research shortlist, not a ranking.

Stock	Standout Attribute	Key Metrics	Primary Risk
Poly Medicure	22.0% ROE	PE 58.0, ROE 22.0%, D/E 0.05	The rich valuation multiple prices in continued strong growth, and any slowdown in export markets or increased competition from Chinese medical device manufacturers could pressure the premium the stock currently commands.
Advanced Enzyme Technologies	D/E 0.02 (near-zero debt)	PE 32.0, ROE 16.0%, D/E 0.02	Enzyme technology sales are exposed to customer concentration risk in select nutraceutical and pharma accounts, and any loss of a key long-term customer relationship could disproportionately affect near-term revenue.
Medicamen Biotech	MCap Rs 430 Cr, lower coverage	PE 18.0, ROE 14.0%, D/E 0.10	Medicamen's small market capitalisation means limited trading liquidity, and its concentration in select emerging export markets carries currency and regulatory risk specific to those geographies.
HLL Lifecare	D/E 0.05 (near-zero debt)	PE 28.0, ROE 10.0%, D/E 0.05	As a government-owned enterprise, HLL Lifecare's pricing and contract terms with public health programmes are subject to government policy decisions rather than pure market negotiation, which can affect margin flexibility.
TTK Healthcare	MCap Rs 1,080 Cr, lower coverage	PE 24.0, ROE 13.0%, D/E 0.10	TTK Healthcare's smaller scale across multiple diversified segments means it lacks the category leadership and pricing power that more focused, larger competitors have in each of its individual product lines.

Why Do These Medical Devices and Healthcare Products Manufacturing Stocks Receive Comparatively Lower Coverage?

Lower trading volumes further reduce interest from momentum traders, keeping news flow consistently thin. Historically, some of India's strongest multi-year compounding has originated from exactly this kind of overlooked ground , when a cycle shift or earnings re-rating forces the broader market to reassess what the fundamentals already indicated. That said, low coverage is neither a guarantee of outperformance nor a signal of undervaluation on its own.

What Factors Should Investors Evaluate in Medical Device Lesser-Known Medical Devices and Healthcare Products Manufacturing Stocks?

• Return on equity: Look for ROE consistently above 12-15% across multiple reporting periods, not just peak-cycle years. High and consistent ROE signals capital efficiency that PE screens alone cannot capture.
• Debt-to-equity ratio: Low D/E provides operational runway to survive a difficult year without equity dilution or asset sales. A D/E below 0.30 is generally considered low leverage for non-financial companies.
• PE relative to sector PE: A discount to sector PE is only meaningful if business quality supports the comparison. Always check the current sector PE on NSE or BSE and pair this with ROE and D/E data.
• Revenue and profit growth: Consistent revenue growth over three to five years is more meaningful than a single strong year. Check the quarterly results section on NSE (nseindia.com) for the complete trend.
• Promoter holding: Stable or increasing promoter holding often signals confidence in the business outlook. Significant promoter selling should prompt additional scrutiny. Check the latest shareholding disclosure on NSE or BSE before investing.
• Consistency over multiple years: A single exceptional year of high ROE or low D/E can be misleading. Look for patterns across 3-5 years of annual reports. Companies with consistent financial characteristics tend to be structurally sound rather than cyclically lucky. Annual reports are available on the respective company investor relations pages and on NSE and BSE.

Key Risks to Evaluate in Under-the-Radar Medical Devices and Healthcare Products Manufacturing Stocks

• Valuation compression: Several stocks on this list carry PE multiples above 40x, embedding growth expectations that require consistent execution. Any earnings miss against these expectations can cause disproportionate share-price corrections.
• Low trading liquidity: Smallcap medical devices and healthcare products manufacturing stocks can move sharply on modest volumes. Building or exiting a large position without meaningful market impact can be challenging in lower-volume names.
• Input-cost inflation: Many medical devices and healthcare products manufacturing companies face raw material cost volatility. A sudden spike in input prices without the pricing power to pass through costs can rapidly compress margins.
• Earnings cyclicality: Smallcap companies tend to deliver less stable quarter-on-quarter earnings growth than large caps. Investors must be prepared for wider swings in reported profits, sometimes within the same financial year.
• Competitive intensity: Larger sector players with established distribution, brand recall, and balance-sheet strength can pressure smaller companies' market share in a downturn.

How to Research and Invest in Medical Device Stocks in India

Start with the business model. Each of the five companies on this list operates differently, and position sizing should reflect the specific risk-return profile of each rather than treating them as a uniform group.

Verify independently. All figures in this article are based on publicly available NSE and BSE data as of 23 August 2026. Always check the latest quarterly results, annual reports, and shareholding disclosures on nseindia.com or bseindia.com before investing.

Use a screener to compare. The Univest Screener allows investors to apply PE, ROE, and D/E filters on live market data to build a comparison shortlist across the medical devices and healthcare products manufacturing sector.

Diversify across names where relevant. Concentrating entirely in one smallcap medical device stocks amplifies single-stock event risk. Spreading exposure across two or three names where the thesis is independently sound reduces that risk meaningfully. Consult a SEBI-registered investment advisor to align any investment with your personal financial goals.

Track earnings trends, not just a point-in-time snapshot. The metrics shown in this article reflect data as of 23 August 2026. These figures will change with each quarterly result. Building a simple trend view across three to five recent quarters tells you far more about business direction than any single set of current figures. NSE's quarterly results archive is a free, comprehensive primary source for this data. Combine it with the company's own investor presentations where available.

Key Takeaways on Medical Device Stocks

• The five medical device stocks covered here represent a range of market caps and business models within the medical device sector.
• Each of these medical device stocks has been selected based on publicly available fundamental data as of 23 August 2026.
• Investors researching medical device stocks should verify all figures on NSE or BSE directly before making any decision.
• The medical device sector has more depth than the top three names. These medical device stocks are the starting point for broader exploration.
• No medical device stocks selection is permanent. Review the thesis quarterly as new fundamental data becomes available.

Conclusion

The five medical device stocks companies covered in this article , Poly Medicure (ROE 22.0%), Advanced Enzyme Technologies (D/E 0.02), Medicamen Biotech (D/E 0.10), HLL Lifecare (D/E 0.05), and TTK Healthcare (D/E 0.10) , each present a distinct profile. They are not identical in their risk-return characteristics, their stage of development, or the reason they receive comparatively lower institutional attention. Investors researching medical device stocks in India should evaluate each company independently using its own financial history, management track record, and position within the sector before drawing any conclusion.

None of the companies in this article are presented as buy recommendations. The medical device sector carries market, operational, and valuation risks that affect each of these five companies differently. Please consult a SEBI-registered investment advisor before making any investment decision.

Frequently Asked Questions on Under the Radar Medical Device Stocks

Which medical device stocks are flying under the radar in India?

Ans. Five medical device stocks that receive comparatively lower institutional coverage in India are Poly Medicure, Advanced Enzyme Technologies, Medicamen Biotech, HLL Lifecare, and TTK Healthcare. Each has a different fundamental profile. Treating these medical device stocks as research starting points, not buy signals, is advisable. Verify all data on NSE or BSE before investing.

Are smallcap medical device stocks suitable for long-term investment?

Ans. Smallcap medical device stocks can offer higher potential returns than large-cap peers in a favourable cycle, but they also carry greater risks: lower liquidity, limited analyst coverage, and higher earnings volatility. Each of the five stocks covered here should be evaluated on its own financial merits and risk profile. Consult a SEBI-registered advisor before investing.

What are the key metrics to check in medical device stocks?

Ans. Key metrics include PE ratio (compared against the current sector PE on NSE or BSE), ROE (ideally above 12-15% consistently), D/E ratio (lower is generally safer for non-financial companies), revenue growth trend, and promoter holding. No single metric should be used in isolation.

Is Poly Medicure a good stock to research?

Ans. Poly Medicure has a PE of 58.00 and an ROE of 22.00%, with a D/E of 0.05 and a 52-week range of Rs 1780.0 to Rs 3100.0. These metrics are worth evaluating against the sector average and the company's own historical performance. Verify all data on NSE before investing.